Announcing a new article publication for BIO Integration journal. Fenofibrate (FF) is a BCS class II compound whose poor solubility poses challenges in drug delivery and bioavailability. Solid self-micro emulsifying drug delivery systems (S-SMEDDS) have emerged as a promising solution to address these issues. These systems are aimed at enhancing the solubility and dissolution rates of poorly soluble drugs, such as FF, by formulating them into solid dosage forms.FF solubility was investigated in various oils, surfactants, and co-surfactants to identify the most suitable components for formulating S-SMEDDS. The preparation of S-SMEDDS was carefully evaluated according to parameters including drug content, morphological characteristics, and structural features. Two methods, freeze-drying, and spray-drying, were compared for their efficacy in producing S-SMEDDS. Additionally, in vitro dissolution studies were conducted to assess the dissolution rates of FF-loaded S-SMEDDS tablets compared with conventional tablets. https://www.scienceopen.com/hosted-document?doi=10.15212/bioi-2024-0010

Announcing a new article publication for BIO Integration journal. Esomeprazole (ESO) gastro-resistant tablets (40 mg) are sold under the brand name, Zosa, which effectively manages conditions associated with the overproduction of gastric acid, including peptic ulcer disease and Zollinger-Ellison syndrome. The present study quantifies impurities in esomeprazole using advanced analytical techniques known as analytical quality by design with high-performance liquid chromatography.Buffer selection (pH 7.6) and mobile phase composition (75:25 v/v) were optimized utilizing a YMC C18 column (150 mm × 4.6 mm; particle size, 3 ?m) with a flow rate of 1.0 mL/min. The analyte was monitored with a UV/PDA detector at a wavelength of 280 nm. The stability-indicating nature of the method was confirmed based on forced degradation studies. The method validation was performed per ICH guidelines. Linearity, specificity, limit of detection, limit of quantification, precision, accuracy, solution stability,… 

Ein experimentelles Medikament von Merck & Co., das Säuglinge vor Erkrankungen durch das Respiratorische Synzytialvirus schützen soll, war in einer fortgeschrittenen Testphase erfolgreich , teilte das Unternehmen am Dienstag mit.In einer Stellungnahme teilte Merck mit, dass die Therapie, ein Antikörper namens Clesrovimab, ihre wichtigsten Sicherheits- und Wirksamkeitsziele in einer placebokontrollierten Studie mit mehr als 3.600 gesunden oder Frühgeborenen erreicht habe . Zu diesen Zielen gehörten die Häufigkeit von RSV-bedingten Infektionen der unteren Atemwege, die im Verlauf von fünf Monaten ärztlicher Behandlung bedurften, im Vergleich zu Placebo, sowie der Prozentsatz der Patienten, bei denen bestimmte Arten von Nebenwirkungen auftraten. https://clinicaltrials.gov/study/NCT04767373